Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HTR1D | P28221 | 1/20 | 0.33 |
| ▸ | HTR1B | P28222 | 1/20 | 0.33 |
| ▸ | FPR2 | P25090 | 2/20 | 0.33 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3734749 | 0.87 | ALDH1A1 (0.38) | ALDH1A1KDM4ENPC1RAB9AADRA2A | |
| SCHEMBL7571795 | 0.83 | ALDH1A1 (0.37) | ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL645698 | 0.83 | ALDH1A1 (0.36) | ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL15528122 | 0.83 | TXN (0.37) | ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL11334976 | 0.79 | ALDH1A1 (0.44) | ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL11335584 | 0.79 | ALDH1A1 (0.34) | ALDH1A1KDM4ENPC1RAB9AADRA2A | |
| SCHEMBL145933 | 0.79 | — | — | |
| SCHEMBL384128 | 0.78 | ALDH1A1 (0.37) | ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7766524 | 0.78 | ALDH1A1 (0.41) | ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7545549 | 0.77 | MMP1 (0.32) | ALDH1A1KDM4EADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2111414-B1 | GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS | UNIV INDIANA RES & TECH CORP (US) | 2014-07-02 | — | — | EP | claimed |
| US-20130157953-A1 | TREATMENT OF CARDIAC CONDITIONS | ZEALAND PHARMA A/S (DK) | 2013-06-20 | — | — | US | claimed |
| EP-2443146-A1 | GIP RECEPTOR-ACTIVE GLUCAGON COMPOUNDS | Indiana University Research And Technology Corporation (US) | 2012-04-25 | — | — | EP | claimed |
| JP-2011524418-A | — | — | 2011-09-01 | — | — | JP | claimed |
| EP-2307037-A1 | GLUCAGON ANALOGS EXHIBITING ENHANCED SOLUBILITY AND STABILITY IN PHYSIOLOGICAL PH BUFFERS | Indiana University Research and Technology Corporation (US) | 2011-04-13 | — | — | EP | claimed |
| WO-2010148089-A1 | GIP RECEPTOR-ACTIVE GLUCAGON COMPOUNDS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2010-12-23 | — | — | WO | claimed |
| US-20100190701-A1 | GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2010-07-29 | — | — | US | claimed |
| WO-2009155257-A1 | GLUCAGON ANALOGS EXHIBITING ENHANCED SOLUBILITY AND STABILITY PHYSIOLOGICAL PH BUFFERS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2009-12-23 | — | — | WO | claimed |
| WO-2021030752-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021030792-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021030794-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021030799-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
| EP-3634978-A1 | TAU AGGREGATION INHIBITORS | Adrx, Inc. (US) | 2020-04-15 | — | — | EP | disclosed |
| WO-2018226992-A1 | TAU AGGREGATION INHIBITORS | ADRX, INC. (US) | 2018-12-13 | — | — | WO | disclosed |
| EP-2249853-A1 | ESTER-BASED PEPTIDE PRODRUGS | Indiana University Research and Technology Corporation (US) | 2010-11-17 | — | — | EP | disclosed |
| EP-2217701-A2 | GLUCAGON ANTAGONISTS | Indiana University Research and Technology Corporation (US) | 2010-08-18 | — | — | EP | disclosed |
| WO-2010071807-A1 | AMIDE BASED GLUCAGON SUPERFAMILY PEPTIDE PRODRUGS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2010-06-24 | — | — | WO | disclosed |
| WO-2009155258-A2 | GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009099763-A1 | ESTER-BASED PEPTIDE PRODRUGS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009058662-A2 | GLUCAGON ANTAGONISTS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190701-A1 | GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS | GLP1R, GCGR, GHRHR | ELANE 4204/4885ALDH1A1 4232/4885KDM4E 241/4885 |
| US-20130157953-A1 | TREATMENT OF CARDIAC CONDITIONS | GLP1R, GCGR, TNNT2 | ELANE 1461/4885ALDH1A1 2934/4885KDM4E 3010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.